Long-term impact of renin-angiotensin system inhibitors for secondary prevention in patients with chronic kidney disease who underwent percutaneous coronary intervention-Reference-Cited by-同舟云学术

Long-term impact of renin-angiotensin system inhibitors for secondary prevention in patients with chronic kidney disease who underwent percutaneous coronary intervention

Published:2022-08-30 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Fukase Tatsuya¹,Dohi Tomotaka¹,Nishio Ryota¹,Takeuchi Mitsuhiro¹,Takahashi Norihito¹,Chikata Yuichi¹,Endo Hirohisa¹,Doi Shinichiro¹,Nishiyama Hiroki¹,Okai Iwao¹,Iwata Hiroshi¹,Okazaki Shinya¹,Miyauchi Katsumi¹,Daida Hiroyuki¹,Minamino Tohru¹

Affiliation:

1. Juntendo University Graduate School of Medicine

Abstract

Abstract The impact of renin-angiotensin system (RAS) inhibitors for secondary prevention in patients with coronary artery disease and coexisting chronic kidney disease (CKD) in the long-term remains unclear. Therefore, we investigated how RAS inhibitor use affects long-term clinical outcomes in patients with CKD who underwent percutaneous coronary intervention (PCI). A total of 1190 patients with CKD who underwent their first PCI between 2000 and 2018 were included in this study, and were divided into two groups based on the presence or absence of RAS inhibitor use. In total, 293 patients (24.6%) developed 3-point major adverse cardiovascular events (3P-MACE), including cardiovascular death, non-fatal acute coronary syndrome and non-fatal stroke, and 136 patients (11.4%) developed heart failure (HF). The cumulative incidence rate of 3P-MACE in the RAS inhibitor group was significantly lower than in the non-RAS inhibitor group (31.7% vs. 40.2%, log-rank test, p = 0.034). However, the cumulative incidence rate of admission for HF in the RAS inhibitor group was significantly higher than in the non-RAS inhibitor group (28.2% vs. 13.8%, log-rank test, p < 0.001). In conclusion, the long-term RAS inhibitor use in patients with CKD after PCI could contribute to prevention of cardiovascular events but may increase the risk of HF.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Dandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 21, 20–27 (2007).

2. Robles, N.R., Cerezo, I., & Hernandez-Gallego, R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther. 19, 14–33 (2014).

3. Pfeffer, M.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 327, 669–677 (1992).

4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure;Yusuf S;N Engl J Med.,1991

5. Flather, M.D., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 355, 1575–1581 (2000).